MET and neoplasm: A growing body of data points out that various miRNAs impede the growth of gefitinib-resistant tumours both in vitro and in vivo, meaning these effects can be attributed largely to the manipulation of EGFR/MET pathway and apoptotic cell death (Figure 1).